Health Care & Life Sciences » Biotechnology | Tikcro Technologies Ltd.

Tikcro Technologies Ltd. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
10.00
46.00
60.00
64.00
35
Gross Income
-
10.00
46.00
60.00
64.00
35
SG&A Expense
571.00
427.00
810.00
1,217.00
1,232.00
1,423
EBIT
571.00
437.00
856.00
1,277.00
1,296.00
1,458
Unusual Expense
-
245.00
35.00
-
-
-
Non Operating Income/Expense
579.00
5.00
6.00
3.00
48.00
11
Interest Expense
-
-
-
-
3.00
-
Pretax Income
8.00
677.00
885.00
1,280.00
1,251.00
1,405
Consolidated Net Income
8.00
677.00
885.00
1,280.00
1,251.00
1,405
Net Income
8.00
677.00
885.00
1,280.00
1,251.00
1,405
Net Income After Extraordinaries
8.00
677.00
885.00
1,280.00
1,251.00
1,405
Net Income Available to Common
8.00
677.00
885.00
1,280.00
1,251.00
1,405
EPS (Basic)
0.00
0.08
0.10
0.13
0.13
0.14
Basic Shares Outstanding
8,747.80
8,832.40
8,840.00
9,878.90
9,878.90
9,878.90
EPS (Diluted)
0.00
0.08
0.10
0.13
0.13
0.14
Diluted Shares Outstanding
8,747.80
8,832.40
8,840.00
9,878.90
9,878.90
9,878.90
EBITDA
571.00
427.00
810.00
1,217.00
1,232.00
1,423

About Tikcro Technologies

View Profile
Address
Kiryat Weizmann Science Park
Ness Ziona TA 7403630
Israel
Employees -
Website http://www.tikcro.com
Updated 07/08/2019
Tikcro Technologies Ltd. operates as a biopharmaceutical company. It pursues an early stage biotechnology project generating new antibodies for cancer treatment addressing immune modulation. This project is based on technology from the Weizmann Institute of Science in Israel.